Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1632 1635 1637 1651 1674 1699
This examiner grants 64% of resolved cases
Ekaterina Poliakova-Georgan has handled 688 resolved cases in Tech Center 1600 and Art Unit 1600. The allowance rate of 64.0 percent suggests a moderate to high likelihood of success for patent applications. The median days to allowance is 941, providing a clear expectation for the time required to navigate the prosecution process. This 941 day median is a useful benchmark for applicants to use when planning their filing strategies.
The data shows an interview lift of 18.0 percent, indicating that interviews are a helpful strategy for securing an allowance. This lift, combined with the 64.0 percent allowance rate, suggests that while the examiner is often receptive to written arguments, verbal communication offers a distinct advantage across the 688 resolved cases. Practitioners should consider the 18.0 percent lift as a reason to engage the examiner directly during prosecution to resolve any outstanding rejections efficiently.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18380871 | CONJUGATES OF SIRNA AND ANTISENSE OLIGONUCLEOTIDES (SIRNASO) AND METHODS OF USE IN GENE SILENCING | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17919459 | COMPOSITIONS AND METHODS FOR INHIBITING TDP-43 AND FUS AGGREGATION | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
| 17310002 | IMMUNOSTIMULATING COMPOSITION | Final Rejection | DAICEL CORPORATION |
| 18571985 | INVERTED CHIMERIC siRNA MOLECULES AND METHODS OF USE THEREOF | Final Rejection | The University of North Carolina at Chapel Hill |
| 18439648 | Inhibition of Tau Propagation | Non-Final OA | The Regents of the University of California |
| 18007609 | NUCLEIC ACID MOLECULE HAVING IMPROVED STABILITY, AND USE THEREOF | Final Rejection | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY |
| 18577797 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING AGE-RELATED CONDITIONS | Non-Final OA | The Hong Kong University of Science and Technology |
| 18251562 | VIRAL VECTORS AND NUCLEIC ACIDS FOR USE IN THE TREATMENT OF ILD, PF-ILD AND IPF | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18557516 | COVALENT APTAMERS | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17938209 | BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE | Final Rejection | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18373397 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18302855 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17375785 | METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER | Final Rejection | Genzyme Corporation |
| 18553729 | GENE THERAPY FOR TREATING BETA-HEMOGLOBINOPATHIES | Non-Final OA | ShanghaiTech University |
| 18360505 | COMPOSITIONS AND METHODS FOR TREATING CEREBROSPINAL FLUID DISORDERS | Non-Final OA | The Children's Medical Center Corporation |
| 18247152 | METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS | Final Rejection | Albert Einstein College of Medicine |
| 18027883 | CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS | Non-Final OA | TriSalus Life Sciences, Inc. |
| 18278494 | ALLELE-SPECIFIC GENOME EDITING OF THE NR2E3 MUTATION G56R | Final Rejection | UNIVERSITÉ DE MONTPELLIER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy